South East Asia Pharmaceutical Contract Development and Manufacturing Market to be worth $4.2 Billion by 2030

According to this latest publication from Meticulous Research®, the South East Asia Pharmaceutical Contract Development and Manufacturing Market is expected to reach $4.2 billion by 2030 at a CAGR of 8.3% from 2023 to 2030.The growth of the South East Asia pharmaceutical contract development and manufacturing market is attributed to the complex manufacturing requirements of the pharmaceutical industry, increasing investment in pharmaceutical R&D, rising demand for generic medicines and biologics, patent expiration, and increasing government funding for drug development and research. In addition, the growing demand for cell and gene therapies and personalized medicines and growth in high potency active pharmaceutical ingredients (HPAPI) and antibody-drug conjugates (ADC) markets are expected to offer significant opportunities for the growth of the pharmaceutical contract development and manufacturing market. However, the lack of skilled professionals is challenging the growth of this market.

Download Sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5675

Key Players

The key players operating in the South East Asia pharmaceutical contract development and manufacturing market are Aenova Group (Germany), Wuxi Biologics, Inc. (China), Vetter Pharma International GmbH (Germany), Catalent, Inc. (U.S.), Lonza Group Ltd. (Switzerland), Almac Group (U.K.), Eurofins Scientific (France), Thermo Fisher Scientific, Inc. (U.S.), Jubilant Life Science Limited (India), Aurobindo Pharma Ltd. (India), APD Pharmaceutical (Singapore), and Esco Aster Pte. Ltd. (Singapore).

South East Asia Pharmaceutical Contract Development and Manufacturing Market: Future Outlook

The South East Asia pharmaceutical contract development and manufacturing market is segmented by Type (Pharmaceutical Manufacturing Services {Active Pharmaceutical ingredient (API) Manufacturing Services and Finished Dosage Forms (FDF) Manufacturing Services [Parenteral/Injectable Manufacturing Services, Tablet Manufacturing Services, Capsule Manufacturing Services, Oral Liquid Manufacturing Services, and Other Formulations]}, Drug Development Services, and Biologics Manufacturing Services{Active Pharmaceutical ingredient (API) Manufacturing Services and Finished Dosage Forms (FDF) Manufacturing Services}), End User (Large Pharmaceutical Companies, Small & Mid-Size Pharmaceutical Companies, and Generic Pharmaceutical Companies), and Countries. The study also evaluates industry competitors and analyzes their market share at the country level.

Among all types studied in this report, in 2023, the pharmaceutical manufacturing services segment is expected to account for the largest share of the South East Asia pharmaceutical contract development and manufacturing market. The pharmaceutical manufacturing services segment is further segmented into active pharmaceutical ingredient (API) manufacturing services and finished dosage forms (FDF) manufacturing services. The largest share of this segment is attributed to the need to reduce manufacturing costs, to bring a new drug to the market quickly at the lowest possible cost, the requirement for high-quality bulk manufacturing, and the growing demand for generic drugs.

Speak to Analyst: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5675

Among all end users studied in this report, the generic pharmaceutical companies segment is expected to register the highest CAGR over the forecast period. The growth of this end-user segment is driven by the increasing competition in the generic market, leading to pricing pressure and the growing inclination of these companies toward the use of cutting-edge technologies offered by contract development and manufacturing firms.

This research report comprehensively analyzes major countries: Indonesia, Vietnam, Thailand, Singapore, Philippines, Malaysia, and the rest of South East Asia. Singapore is expected to grow at the highest CAGR during the forecast period in South East Asia's pharmaceutical contract development and manufacturing market. According to the Singapore Economic Development Board (EDB), Singapore is a choice of location for many pharmaceutical companies for the development and production of pharmaceutical products, thus, increasing numbers of pharmaceutical companies in the country is driving the market growth. According to the Ministry of Health, the Singapore National Health Expenditure could increase to $43 billion in 2030. This increase indicates the high focus of the country on its healthcare infrastructure, making it a suitable location for research that expands the drug pipeline.

Buy Now: https://www.meticulousresearch.com/Checkout/70375935

Key questions answered in the report:

Which are the high-growth market segments in terms of type, end user, and country?

What was the historical market for pharmaceutical contract development and manufacturing services in South East Asia?

What are the market forecasts and estimates for the period 2023-2030?

What are the major drivers, restraints, challenges, and opportunities in the south east asia pharmaceutical contract development and manufacturing market?

Who are the major players in the south east asia pharmaceutical contract development and manufacturing market?

About Us:

We are the trusted research partners for leading businesses around the world, providing market intelligence focused towards building revenue transformation strategies. Our research is used by Fortune 500 organizations to attain success by scouting next generation revenue opportunities well ahead of their competition.

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

This release was published on openPR.